{"filing":{"accession_number":"0001193125-26-258372","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"d132290d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/d132290d8k.htm"},"events":[{"id":3653,"run_id":3205,"accession_number":"0001193125-26-258372","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"This disclosure announces translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, an anti-APRIL monoclonal antibody candidate. The announcement includes positive preliminary safety findings (no serious adverse events, dose-limiting toxicities, or discontinuations in 49 healthy volunteers up to 320 mg) and supportive pharmacokinetic/pharmacodynamic modeling suggesting potential for less-frequent dosing. While this is a clinical development milestone for a pipeline asset, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure would be material to investors evaluating the company's pipeline progress and risk profile, particularly given the positive safety profile and advancement toward Phase 2 dosing in IgAN patients expected in Q3 2026.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-05","items":[{"id":4649,"accession_number":"0001193125-26-258372","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, an anti-APRIL monoclonal antibody candidate. The announcement includes positive preliminary safety findings (no serious adverse events, dose-limiting toxicities, or discontinuations in 49 healthy volunteers up to 320 mg) and supportive pharmacokinetic/pharmacodynamic modeling suggesting potential for less-frequent dosing. While this is a clinical development milestone for a pipeline asset, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure would be material to investors evaluating the company's pipeline progress and risk profile, particularly given the positive safety profile and advancement toward Phase 2 dosing in IgAN patients expected in Q3 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:10.792217+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4649,"accession_number":"0001193125-26-258372","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, an anti-APRIL monoclonal antibody candidate. The announcement includes positive preliminary safety findings (no serious adverse events, dose-limiting toxicities, or discontinuations in 49 healthy volunteers up to 320 mg) and supportive pharmacokinetic/pharmacodynamic modeling suggesting potential for less-frequent dosing. While this is a clinical development milestone for a pipeline asset, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure would be material to investors evaluating the company's pipeline progress and risk profile, particularly given the positive safety profile and advancement toward Phase 2 dosing in IgAN patients expected in Q3 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:10.792217+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-05"}]}